Samuel M. Goldman, MD, MPH; Frances M. Weaver, PhD; Kevin T. Stroupe, PhD; et al.
free access
has audio
JAMA Neurol. 2023;80(7):673-681. doi:10.1001/jamaneurol.2023.1168
This cohort study assesses the association between the contaminated water supply at Camp Lejeune and incidence of Parkinson disease among veterans who resided there between 1975 and 1985.
-
Podcast:
Risk of Parkinson Disease Among Camp Lejeune Veterans
Joanna M. Wardlaw, MD; Lisa J. Woodhouse, PhD; Iris I. Mhlanga, MSc; et al.
open access
JAMA Neurol. 2023;80(7):682-692. doi:10.1001/jamaneurol.2023.1526
This randomized clinical trial examines treatment outcomes with isosorbide mononitrate and cilostazol in patients with symptomatic cerebral small vessel disease.
Michael Hittle, BS; William J. Culpepper, PhD; Annette Langer-Gould, MD, PhD; et al.
open access
JAMA Neurol. 2023;80(7):693-701. doi:10.1001/jamaneurol.2023.1135
This cohort study analyzes data from representative private, military, and public health insurance data sets to calculate the national prevalence of multiple sclerosis among Hispanic, non-Hispanic Black, and non-Hispanic White individuals in the United States.
Tomas Kalincik, MD, PhD; Sifat Sharmin, PhD; Izanne Roos, MBChB, PhD; et al.
free access
JAMA Neurol. 2023;80(7):702-713. doi:10.1001/jamaneurol.2023.1184
This comparative effectiveness research study compares autologous hematopoietic stem cell transplant (AHSCT) vs fingolimod, natalizumab, and ocrelizumab for patients with relapsing-remitting multiple sclerosis.
Nadinda A. M. van der Ende, MD; Bob Roozenbeek, MD, PhD; Lucas E. M. Smagge, MD; et al.
free access
JAMA Neurol. 2023;80(7):714-722. doi:10.1001/jamaneurol.2023.1262
This randomized clinical trial of individuals with ischemic stroke assesses the safety and efficacy of treatment with a dual plasminogen activator vs usual treatment with intravenous alteplase.
Michelle C. Johansen, MD, PhD; Wen Ye, PhD; Alden Gross, PhD; et al.
free access
JAMA Neurol. 2023;80(7):723-731. doi:10.1001/jamaneurol.2023.1331
This cohort study uses pooled data from 6 US population-based cohort studies to assess whether incident myocardial infarction is associated with changes in cognition immediately after in the years following the event.
Steven J. Warach, MD, PhD; Anna Ranta, PhD; Joosup Kim, PhD; et al.
free access
JAMA Neurol. 2023;80(7):732-738. doi:10.1001/jamaneurol.2023.1449
This cohort study evaluates rates of symptomatic intracranial hemorrhage following stroke with tenecteplase vs alteplase.
Chao Zhu, PhD; Tomas Kalincik, MD, PhD; Dana Horakova, MD, PhD; et al.
free access
JAMA Neurol. 2023;80(7):739-748. doi:10.1001/jamaneurol.2023.1542
This cohort study investigates differences in the effectiveness and treatment persistence between dimethyl fumarate, fingolimod, and ocrelizumab among patients with relapsing-remitting multiple sclerosis who switched from natalizumab.
Ruben Smith, MD, PhD; Douglas Hägerström, MD; Daria Pawlik, MD; et al.
open access
JAMA Neurol. 2023;80(7):749-756. doi:10.1001/jamaneurol.2023.1323
This study aims to prospectively study the added clinical value of positron emission tomography detecting tau pathology in Alzheimer disease.